Posted inClinical Updates news Ophthalmology
Clobetasol Propionate Ophthalmic Suspension 0.05%: A New Therapeutic Milestone in Post-Cataract Surgery Inflammation and Pain Management
This review synthesizes clinical evidence for CPN 0.05% (BYQLOVI®), highlighting its rapid efficacy, superior pain resolution, and favorable safety profile compared to traditional ocular steroids following cataract surgery.